Evaluating the safety and efficacy of argatroban locking solution in the prevention of the dysfunction of haemodialysis central venous catheters: a study protocol for a randomized controlled trial | Zendy

Yiqin Wang | Zendy; Chao Liu | Zendy; Li Zhang | Zendy; Jijun Li | Zendy; Lei Zhang | Zendy; Yong Wang | Zendy; Hanyu Zhu | Zendy; Xueying Cao | Zendy; Di Wu | Zendy; Jie Wu | Zendy; Shupeng Lin | Zendy; Zhe Feng | Zendy; Guangyan Cai | Zendy; Xiangmei Chen | Zendy; Xuefeng Sun | Zendy

Open Access

Evaluating the safety and efficacy of argatroban locking solution in the prevention of the dysfunction of haemodialysis central venous catheters: a study protocol for a randomized controlled trial

Author(s) -

Yiqin Wang,

Chao Liu,

Li Zhang,

Jijun Li,

Lei Zhang,

Yong Wang,

Hanyu Zhu,

Xueying Cao,

Di Wu,

Jie Wu,

Shupeng Lin,

Zhe Feng,

Guangyan Cai,

Xiangmei Chen,

Xuefeng Sun

Publication year - 2021

Publication title -

annals of palliative medicine

Language(s) - English

Resource type - Journals

eISSN - 2224-5839

pISSN - 2224-5820

DOI - 10.21037/apm-20-1641

Subject(s) - medicine , argatroban , catheter , dialysis catheter , anesthesia , anticoagulant , heparin , thrombosis , adverse effect , central venous catheter , surgery , partial thromboplastin time , dialysis , coagulation , thrombin , platelet

Use of anticoagulant as lock solutions is an important method to maintain the function of haemodialysis (HD) central venous catheters (CVCs), and the common anticoagulants heparin and citrate are not suitable for some patients. Argatroban can inhibit thrombin directly, has a definite anticoagulant effect, and is expected to be a new anticoagulant for CVC lock solutions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research